167 related articles for article (PubMed ID: 19069481)
21. Bladder-sparing therapy for muscle-infiltrating bladder cancer.
Pansadoro V; Emiliozzi P
Nat Clin Pract Urol; 2008 Jul; 5(7):368-75. PubMed ID: 18560383
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy.
Bruins HM; Huang GJ; Cai J; Skinner DG; Stein JP; Penson DF
J Urol; 2009 Nov; 182(5):2182-7. PubMed ID: 19758623
[TBL] [Abstract][Full Text] [Related]
23. The risk factor for urethral recurrence after radical cystectomy in patients with transitional cell carcinoma of the bladder.
Cho KS; Seo JW; Park SJ; Lee YH; Choi YD; Cho NH; Yang SC; Hong SJ
Urol Int; 2009; 82(3):306-11. PubMed ID: 19440019
[TBL] [Abstract][Full Text] [Related]
24. Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000.
David KA; Mallin K; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
Cancer; 2009 Apr; 115(7):1435-47. PubMed ID: 19215030
[TBL] [Abstract][Full Text] [Related]
25. Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer.
Stein JP; Penson DF; Lee C; Cai J; Miranda G; Skinner DG
J Urol; 2009 May; 181(5):2052-8; discussion 2058-9. PubMed ID: 19286213
[TBL] [Abstract][Full Text] [Related]
26. [Results of the combined treatment of bladder cancer patients].
Aslamazov EG; Doldurov GS; Sarkisian IuKh; Agafonova GB
Urol Nefrol (Mosk); 1984; (4):27-30. PubMed ID: 6474624
[No Abstract] [Full Text] [Related]
27. The prognostic significance of pathologic stage T0 on organ-confined bladder transitional cell carcinoma following radical cystectomy.
Cho KS; Seo JW; Park SY; Cho NH; Choi YD; Yang SC; Hong SJ
Urol Int; 2008; 81(4):394-8. PubMed ID: 19077398
[TBL] [Abstract][Full Text] [Related]
28. Relook TURBT in superficial bladder cancer: its importance and its correlation with the tumor ploidy.
Dwivedi US; Kumar A; Das SK; Trivedi S; Kumar M; Sunder S; Singh PB
Urol Oncol; 2009; 27(5):514-9. PubMed ID: 18639472
[TBL] [Abstract][Full Text] [Related]
29. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
Kaufman DS; Winter KA; Shipley WU; Heney NM; Wallace HJ; Toonkel LM; Zietman AL; Tanguay S; Sandler HM
Urology; 2009 Apr; 73(4):833-7. PubMed ID: 19100600
[TBL] [Abstract][Full Text] [Related]
30. [Prognosis for therapeutic effectiveness of radiotherapy in the combined treatment of cancer].
Ivanov SD
Vopr Onkol; 2008; 54(4):483-9. PubMed ID: 18942405
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcome of chemoradiotherapy for T1G3 bladder cancer.
Inoue M; Ishioka J; Fukuda H; Kageyama Y; Saito Y; Higashi Y
Int J Urol; 2008 Aug; 15(8):747-50. PubMed ID: 18786198
[TBL] [Abstract][Full Text] [Related]
32. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.
Cho KS; Seo HK; Joung JY; Park WS; Ro JY; Han KS; Chung J; Lee KH
J Urol; 2009 Dec; 182(6):2625-30. PubMed ID: 19836779
[TBL] [Abstract][Full Text] [Related]
33. The treatment of patients with bladder cancer: let's not forget the past!
Stein JP
J Urol; 2005 Sep; 174(3):814-5. PubMed ID: 16093959
[No Abstract] [Full Text] [Related]
34. Adjuvant radiation therapy for muscle-invasive bladder cancer.
Zaghloul MS
Tunis Med; 2005 Dec; 83 Suppl 12():92-3. PubMed ID: 16430078
[No Abstract] [Full Text] [Related]
35. Oncological followup after radical cystectomy for bladder cancer-is there any benefit?
Volkmer BG; Kuefer R; Bartsch GC; Gust K; Hautmann RE
J Urol; 2009 Apr; 181(4):1587-93; discussion 1593. PubMed ID: 19233433
[TBL] [Abstract][Full Text] [Related]
36. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes.
Boudreaux KJ; Chang SS; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Clark PE
Cancer; 2009 Feb; 115(4):770-5. PubMed ID: 19152431
[TBL] [Abstract][Full Text] [Related]
37. [Prognosis of local recurrence after radical cystectomy for bladder cancer].
Fukuta F; Honma I; Muto M; Masumori N; Tsukamoto T
Hinyokika Kiyo; 2009 Aug; 55(8):469-73. PubMed ID: 19764530
[TBL] [Abstract][Full Text] [Related]
38. [The frequency of recurrences and metastases of bladder cancer following a radical course of radiotherapy].
Pereslegin IA; Mufazalov FF
Vestn Rentgenol Radiol; 1992; (3):57-8. PubMed ID: 1441213
[TBL] [Abstract][Full Text] [Related]
39. Editorial comment on: detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience.
Dalbagni G
Eur Urol; 2010 May; 57(5):849. PubMed ID: 19524355
[No Abstract] [Full Text] [Related]
40. Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.
Catto JW; Abbod MF; Linkens DA; Larré S; Rosario DJ; Hamdy FC
Clin Cancer Res; 2009 May; 15(9):3150-5. PubMed ID: 19336522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
